Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04826237 · ClinicalTrials.gov registry record · Phase 4
Oral Statins and Protection From Hearing Loss
A Phase 4 study of Sudden Sensorineural Hearing Loss, sponsored by Northwestern University.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 100
- Enrollment target
- 1
- Study location
NCT04826237 is a Phase 4 study of Sudden Sensorineural Hearing Loss that is actively recruiting participants, run by Northwestern University. The registered enrollment target is 100 participants. The trial reports 1 study location across 1 state.
The verdict
NCT04826237, a Phase 4 study of Sudden Sensorineural Hearing Loss, is actively recruiting participants, sponsored by Northwestern University.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
A small clinical trial for idiopathic sudden sensorineural hearing loss (ISSNHL). Will the addition of an oral statin to the standard treatment (oral methylprednesolone and the salvage therapy of intratympanic dexamethasone) improve the treatment outcome for patients with ISSNHL? This study will compare the two treatments and quantitatively evaluate hearing and speech discrimination and have the patients subjectively evaluate tinnitus.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Statin
- DRUG methylprednisolone
- DRUG dexamethasone
Study Locations (1)
Illinois
- Northwestern Memorial Hospital - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2023-02-09 |
| Est. Completion | 2025-12-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04826237
The ClinicalTrials.gov registry entry for NCT04826237 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Sudden Sensorineural Hearing Loss appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT04826237 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT04826237 about?
NCT04826237 is a clinical study titled "Oral Statins and Protection From Hearing Loss". A small clinical trial for idiopathic sudden sensorineural hearing loss (ISSNHL). Will the addition of an oral statin to the standard treatment (oral methylprednesolone and the salvage therapy of intratympanic dexamethasone) improve the treatment outcome for patients with ISSNHL? This study will com...
What is the current status of trial NCT04826237?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 100 participants. The study started on 2023-02-09. Estimated completion is 2025-12-31.
What conditions does trial NCT04826237 study?
This clinical trial studies the following conditions: Sudden Sensorineural Hearing Loss.
What interventions are being tested in trial NCT04826237?
The interventions under investigation include: Placebo (DRUG), Statin (DRUG), methylprednisolone (DRUG), dexamethasone (DRUG).
Who is sponsoring clinical trial NCT04826237?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04826237 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.